Expert Access - Personalized Medicine: The Developers, Stakeholders and Beneficiaries

Michael T. Stocum, MS

October 2010

QA Archive


Personalized medicine (PM) extends beyond the clinical laboratory, impacting many different stakeholders in the healthcare community. This session will:

  1. Demonstrate how PM is being utilized in pharma and novel diagnostic product development;
  2. Offer pharma’s perception of the PM space;
  3. Highlight products with relevant PM approaches that are impacting drug labeling;
  4. Demonstrate that returns on investment are already being realized; and
  5. Emphasize that numerous areas exist for laboratory professionals to deliver testing information that significantly alters prescribing behavior going forward.




Mr. Stocum is Founder and Managing Director of Personalized Medicine Partners, LLC, a firm that provides strategic and operational support to biopharmaceutical and diagnostic companies as well as laboratory service providers in the development of integrated therapeutic and biomarker/companion diagnostic programs that form the basis of current and future personalized medicine products (click here for more information about PMP, or go to the company web site). Throughout his career he has developed personalized medicine programs, impacting the drug and diagnostic product development continuum at all stages from research to commercialization. These programs have spanned several therapeutic areas, including infectious diseases, cancer, cardiometabolic diseases, critical care and inflammation. Mr. Stocum has nearly 20 years of life science experience including positions in pharmaceuticals (GlaxoSmithKline) as well as biologics and molecular diagnostics (AkzoNobel Pharma – Organon Teknika division) plus two Biotech start-ups (Xanthon and Tricon Pharmaceuticals).

While in industry, he held positions of increasing responsibility beginning in bench research, then progressing to product, business and commercial development as well as licensing. He has developed or commercialized multiple novel molecular diagnostic products and supported the development of numerous medicines in several disease areas as previously mentioned. Many of these products have sustained commercial success measured in product sales ranging from tens to hundreds of millions of dollars annually. Since leaving GSK just over five years ago to start up Personalized Medicine Partners, he and his partners have delivered on significant value-added projects for more than a fifteen companies.

Mr. Stocum serves as the Chair of the American Association for Clinical Chemistry’s Personalized Medicine Advisory Group and is an active member in the Personalized Medicine Coalition, a non-profit dedicated to advancing the field of Personalized Medicine. He also serves on the Industry Advisory Board for the Professional Science Masters program at North Carolina State University (NCSU). His educational background includes dual BS degrees in Biochemistry and Microbiology with a minor in Genetics, plus an MS in Biotechnology Management, all from NCSU, and included two years of academic research assistantships at NCSU and the National Institutes Health in the National Institute of Environmental Health Sciences. He resides in Raleigh, North Carolina with his wife and two children, ages 10 and 7.


Page Access: